SCHEMBL3535285

SCHEMBL3535285

CN1CCN(c2ccc3nc(-c4n[nH]c5c(NS(C)(=O)=O)cccc45)[nH]c3c2)CC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 11/20 0.65
FLT1 P17948 5/20 0.65
FLT3 P36888 1/20 0.52
KDR P35968 6/20 0.49
PDGFRB P09619 4/20 0.49
ALDH1A1 P00352 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
KDM4E B2RXH2 1/20 0.48
NPC1 O15118 1/20 0.48
POLB P06746 1/20 0.48
RAB9A P51151 1/20 0.48
CDK4 P11802 1/20 0.47
CCNA2 P20248 1/20 0.47
CCND1 P24385 1/20 0.47
CDK2 P24941 1/20 0.47
CCND3 P30281 1/20 0.47
DRD2 P14416 1/20 0.47
HTR7 P34969 1/20 0.47
HTR2B P41595 1/20 0.47
HTR6 P50406 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3541407 0.90 FGFR1 (0.63) FGFR1FLT1FLT3KDRPDGFRB
SCHEMBL3536028 0.90 FGFR1 (0.61) FGFR1FLT1FLT3KDRPDGFRB
SCHEMBL3545051 0.87 FGFR1 (0.63) FGFR1FLT1FLT3KDRPDGFRB
SCHEMBL3543245 0.86 FGFR1 (0.56) FGFR1FLT1FLT3KDRPDGFRB
SCHEMBL3541056 0.86 FGFR1 (0.65) FGFR1FLT1FLT3KDRPDGFRB
SCHEMBL3540105 0.85 FGFR1 (0.61) FGFR1FLT1FLT3KDRPDGFRB
SCHEMBL3532687 0.83 FGFR1 (0.63) FGFR1FLT1FLT3KDRPDGFRB
SCHEMBL3533470 0.82 FGFR1 (0.73) FGFR1FLT1FLT3KDRPDGFRB
SCHEMBL3537816 0.81 FGFR1 (0.70) FGFR1FLT1FLT3KDRPDGFRB
SCHEMBL3533929 0.80 FGFR1 (0.67) FGFR1FLT1FLT3KDRPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7064215-B2 Indazole benzimidazole compounds CHIRON CORPORATION (US) 2006-06-20 US disclosed
EP-1401831-A1 INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS CHIRON CORPORATION (US) 2004-03-31 EP disclosed
US-20030207883-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2003-11-06 US disclosed
WO-2003004488-A1 INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS CHIRON CORPORATION (US) 2003-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207883-A1 Indazole benzimidazole compounds SLCO1B3, SLCO1B1, SLCO4C1 FGFR1 2175/4885FLT1 3562/4885FLT3 1114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.